Oncologist. The. Commentary. Putting Insulin Glargine and Malignancies into Perspective. The Oncologist 2009;14:
|
|
- Garey Long
- 6 years ago
- Views:
Transcription
1 The Oncologist Commentary Putting Insulin Glargine and Malignancies into Perspective GERHARD EHNINGER, ALEXANDER H. SCHMIDT Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany Key Words. Insulin Malignancy Glargine Colon Pancreas Breast Disclosures: Gerhard Ehninger: None; Alexander H. Schmidt: None. The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors or independent peer reviewers. INTRODUCTION...while society expects due diligence in the detection of serious drug side-effects, claims of harm not backed by adequate evidence can provoke unnecessary alarms and anxieties, and seriously interfere with good medical practice. Pocock and Smeeth [1]. Patients with type 2 diabetes have been shown to have a higher risk for cancer. The excess risk compared with nondiabetic matched individuals is 30% for colon cancer, 50% for pancreatic cancer, and 20% for postmenopausal breast cancer [2 4]. These are, however, also associated with obesity, making the causal relationship complex. Further to this, pharmacotherapy for the treatment of diabetes has been shown to be associated with greater cancer mortality, with metformin being neutral and sulfonylureas (hazard ratio [HR], 1.3; 95% CI, ) and insulin (HR, 1.9; 95% CI, ) showing higher mortality [5]. Insulin glargine is a long-acting insulin analog that is identical to human insulin except at position 21 of the A- chain (Asp 3 Gly) and two additional terminal Arg in the B-chain. It was developed in response to a clinical demand for prolonged stable action and, most of all, a lower risk for hypoglycemia. These advanced properties have led to its widespread use as basal insulin in clinical practice. It is, however, unknown whether or not insulin glargine and human insulin are different with respect to mitogenicity. They have so far only been compared in in vitro studies showing that insulin glargine had greater receptor affinity and mitogenic potency [6], but in vivo metabolism of insulin glargine at the injection site and in the circulation suggest low mitogenic potency [7]. OBSERVATIONAL DATA Recently, data from an observational, retrospective cohort study in Germany were published. A significantly lower incidence of cancer for patients on insulin glargine in the unadjusted analysis as well as after adjustment for age and sex (HR, 0.86; 95% CI, ) compared with patients on human insulin [8] were shown. This result was reversed by an additional step, adjusting for insulin doses (HR, 1.14; 95% CI, ). The results of this study were submitted to Diabetologia, the editors of which realized a number of limitations [9]. These ranged from biological implausibility, given the short median period (1.31 years for insulin glargine) of exposure to each of the insulins, to the limited overlap between the dose ranges, the unexplained effect of Correspondence: Gerhard Ehninger, M.D., Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse 74, Dresden, Germany. Telephone: ; Fax: ; gerhard.ehninger@uniklinikum-dresden.de, Web site: Received August 31, 2009; accepted for publication October 31, 2009; first published online in The Oncologist Express on December 10, 2009; available online without subscription through the open access option. AlphaMed Press /2009/$30.00/0 doi: /theoncologist The Oncologist 2009;14:
2 1170 It Is Easier to Seed the Buzz Than to Disprove It Table 1. Risk for malignancy for patients prescribed insulin glargine compared with other insulins in five prospective studies [1] Adjusted hazard Study type Comparator ratio (95% CI) Hemkens et al. [8] German database Human insulin 0.86 ( ) Currie et al. [12] U.K. THIN database Human insulin 0.81 ( ) Jonasson et al. [10] Swedish database Other insulins 1.07 ( ) SDRN Epidemiology Group [11] Scottish database Other insulins 1.02 ( ) Rosenstock et al. [16] Randomized trial Human insulin 0.63 ( ) Abbreviation: CI, confidence interval; SDRN, Scottish Diabetes Research Network; THIN, The Health Improvement Network. insulin glargine on all-cause mortality, the lack of overall difference in cancer risk among the four insulins in the crude analysis, failure to correct for BMI in the dose response analysis, and a number of technical considerations. Three of the six reviewers recommended rejecting the article. Publication of this hypothesis-generating data was finally made, conditional upon other retrospective analyses, which were initiated subsequently [9] (Table 1). A Swedish study identified patients receiving prescriptions for insulin in 2005 from different registries [10] and linked their records to cancer registry data for the two subsequent years. No significant difference in cancer rates was found between patients on insulins other than insulin glargine and those on insulin glargine plus other insulins. Patients who were treated with insulin glargine alone, however, had a higher risk for breast cancer than those on other insulins (relative risk, [RR], 1.99; 95% CI, ). Risks for other malignancies did not differ among the various groups. The authors stated that they had a priori expected a higher risk for all or none of the analyzed cancer types and concluded: We found no statistically significant results for prostate or gastrointestinal cancer, which, again, strengthens the interpretation that the breast cancer results were due to random fluctuation [10]. A Scottish analysis [11] was based on a national diabetes database. Those investigators analyzed all patients exposed to insulin therapy for the calendar years and matched them with cancer registry data up to the end of There was a significantly lower risk for all cancer types with no greater overall risk for breast cancer with insulin glargine. The authors stated that they added a further analysis to examine if the analysis of Hemkens et al. [8] might be biased, because it was restricted to users of insulin glargine who were not using any other insulins concurrently. For this subgroup, they found a higher overall cancer rate (HR, 1.55; 95% CI, ), with more cases of breast cancer in those on insulin glargine than those on nonglargine insulins (HR, 3.39; 95% CI, ; p.004). The authors underlined that they do not expect this to be caused by a different insulin effect but by a biased estimate: We wanted to understand whether restricting the analysis to such a subgroup could lead to a biased estimate of any overall relationship between cancer and insulin glargine, not because we were hypothesising differential effects of insulin glargine that are dependent on concomitant insulin. The authors 11 furthermore discussed that patients using glargine only constituted only a small subset with an allocation bias toward older and generally less healthy patients. They concluded that:... ourprimary hypothesis that exposure to insulin glargine was associated with an adverse effect on total cancer rates or site-specific cancer was refuted, and these data are reassuring in this regard [11]. The U.K. general practice analysis [12] was based on The Health Improvement Network database, representing the most detailed database with carefully defined subcategories according to diabetes therapy. This analysis showed no significant differences in malignancy risk for the four insulin-treated groups (insulin glargine only, neutral protamin Hagedorn [NPH] insulin only, human biphasic insulin only, and analog biphasic insulin only). All publications lacked prespecifications or defined objectives, which causes multiplicity, a serious issue that cannot be controlled for. According to the editorial, the overall null hypothesis was that people treated with insulin analogues were not more likely to be diagnosed with cancer [9]. With regard to this primary objective, none of the additional studies confirmed the findings of the Hemkens et al. [8] analysis. CRITICAL APPRAISAL OF HEMKENS ET AL. [8] The Hemkens et al. [8] paper was recently commented on by Pocock and Smeeth [1], in an article unambiguously entitled Insulin glargine and malignancy: An unwarranted
3 Ehninger, Schmidt 1171 alarm. The comment was recently published in The Lancet, concluding with respect to the Hemkens et al. [8] analyses that...the methods used are fundamentally flawed, making the conclusions unsupportable and highlighting two serious errors, which make the article s findings uninterpretable. These errors are the a posteriori allocation of patients into treatment groups based on follow-up information and the use of mean insulin doses as observed during the follow-up period as baseline covariates in a survival analysis. They further underlined that the emphasized findings for breast cancer in the Swedish study, which was not confirmed in the Scottish analyses, should not be overestimated because of a lack of prespecification and multiplicity. INCLUSION CRITERIA CREATE DISTINCTIVE OBSERVATIONAL GROUPS The Hemkens et al. [8] study suffers from important imbalances between the observational groups (Table 2) that cannot be controlled by adjustment, either because they are not available from the data set, for example, body mass index (BMI) or smoking habits, or because adjustment of actual medically distinctive groups can be misleading. The latter include characteristics of patients in the human insulin group that are excluded in the glargine group: use of shortacting insulins, type 1 diabetes, and use of other (supplementary insulin therapy, conventional therapy) and intensified (intensified conventional therapy) regimens. The author group decided to solely compare patients receiving a long-acting insulin glargine only with patients receiving human insulin irrespective of it being a long- or shortacting insulin or even a combination of both. This is unwise, creating two biologically different cohorts. Patients sufficiently treated with a long-acting or basal insulin only still produce enough endogenous insulin to control postprandial blood glucose. On the other hand, patients receiving both short- and long-acting insulin are mostly lacking endogenous insulin and may even include patients with type 1 diabetes. According to the inclusion criteria, there would be patients with basal insulin only in the human insulin groups as well, but the report gives no deeper information on this. It states, however, representativeness for Germany, which means that the human insulin group would be dominated by patients who need a substitution with basal and bolus insulins because of a severe lack of endogenous insulin. This deduction is empirically supported by the insulin doses for the observational groups [8] 22 U/day in the insulin glargine group versus 37 U/day in the human insulin group; 95% quartiles differ by 59 U/day versus 100 U/day, respectively. All these imbalances are mainly a consequence of the chosen inclusion criteria and could have been prevented Table 2. Group characteristics of patients in the Hemkens et al. [8] study Human insulin group Insulin glargine group NPH insulin and/or regular insulin Type 1 and 2 diabetes Low level or no residual insulin Different regimens: BOT, ICT, CT, SIT Oral antidiabetic agents, 77.2% Insulin glargine without any other insulin Type 2 diabetes only Higher level of endogenous insulin secretion Only one regimen: BOT Oral antidiabetic agents, 92.1% Sulfonylureas, 66.7% Sulfonylureas, 79.8% Abbreviations: BOT, basal supported oral therapy; CT, conventional therapy; ICT, intensified conventional therapy; NPH, neutral protamin Hagedorn; SIT, supplementary insulin therapy. easily either by comparing long-acting glargine with longacting human insulin exclusively or by comparing insulin glargine plus optional bolus insulins with human basal insulin plus optional bolus insulins. However, the two fundamental flaws of the Hemkens et al. [8] study as revealed by Pocock and Smeeth [1] would still persist as a result of the very nature of the available data. HIGHER CALCULATED CANCER INCIDENCE IS CAUSED BY ADJUSTMENT FOR DOSE It must be considered that the Hemkens et al. [8] study primarily shows a significantly lower cancer incidence for patients treated with insulin glargine than for those treated with human insulin. This effect persists after adjustment for age and gender, with an HR of 0.86 (95% CI, ). A further adjustment for dose, based on the observed differences (22 U/day with insulin glargine versus 37 U/day with human insulin) reverses this relationship (HR, 1.14; 95% CI, ). This adjustment was heavily criticized in The Lancet article by Pocock and Smeeth [1] to be based on serious errors [which] make the article s findings unsupportable. Beyond that, one should consider that the substantial difference in dose that is subject to this flawed adjustment can partly or totally be explained as an artificial effect resulting from selective inclusion criteria rather than medical reality. As described above, the inclusion criteria result in a group of patients with a higher degree of residual endogenous insulin in the glargine group, enabling those patients to be treated without bolus insulins, being compared with human insulin patients, many of whom are treated with a combination of basal and bolus insulins, indicating low levels of endogenous insulin secretion. For this reason, an adjustment for mean external insulin doses as performed by
4 1172 It Is Easier to Seed the Buzz Than to Disprove It Hemkens et al. [8] causes a systematic error toward higher cancer risks for insulin glargine because it does not consider the different levels of endogenous insulin. IS THERE A RELATIONSHIP BETWEEN DOSE AND CANCER INCIDENCE? Hemkens et al. [8] present HRs of glargine versus human insulin for three classes of patients, with mean daily doses for each insulin type of 20 U/day, U/day, and 40 U/day. They obtained a significantly higher HR for the glargine group for only the 40 U/day dose, of 1.59 (95% CI, ). The HR for the U/day group (1.01; 95% CI, ) was even lower than that for 20 U/day group (1.13; 95% CI, ). This result raises questions regarding the validity of the regression model used by Hemkens et al. [8] because this model delivered a nearly linear increase in HR with dose from 1.09 (10 U/day) over 1.19 (30 U/day) to 1.31 (50 U/day). Because the basis of the regression calculations is fundamentally flawed anyway, this additional problem seems, however, to be of only minor relevance. There was substantial imbalance within the high-dose class of 40 U/day. Only 13.5% of the insulin glargine patients but 46% of the human insulin patients constituted this high-dose class. This again is caused by the study design. Patients with an overall insulin use 40 U/day (human insulin group, both short- and long-acting insulins) were compared with patients with 40 U/day of basal insulin alone (glargine group), ignoring that these patients additionally had a relevant amount of endogenous insulin, sufficient to avoid the necessity for postprandial bolus insulin. Differences in the dose used may be explained by the BMI of the patients. On the other hand, a rise in BMI is positively correlated with cancer [13]. A recent meta-analysis made from 31 studies showed that an increase in BMI of 5 kg/m 2 led to a significant increase in cancer rates for, among others, colon cancer, pancreatic cancer, and postmenopausal breast cancer in women [14]. The BMI is, however, not available from the AOK (Allgemeine Ortskrankenkasse, the main statutory health insurance in Germany) data set. Therefore, the missing adjustment for BMI makes it impossible to state that there is a dose dependency of cancer risk at all. The Swedish study tried to confirm this dose relationship but failed [10]. Because the Swedish data were adjusted for BMI, this supports the notion that the dose relationship described by Hemkens et al. [8] is not real but a confounding effect of BMI. ARE THE ANALYSES SUPPORTED BY AVAILABLE RANDOMIZED CONTROLLED TRIAL EVIDENCE? Erbel et al. [15] reported data on 125 patients with diabetes after partial or total pancreatectomy resulting from pancreatic carcinoma followed up for a median duration of 22 months. The median survival time was 15 months, with no difference in the time-dependent proportion of patients who survived between insulin glargine users and those with nonglargine insulin treatment (p.04). The authors concluded from their analysis that regular human insulin and insulin glargine may be used to treat diabetes in patients with pancreatic cancer. Rosenstock et al. [16] analyzed the data set from a randomized long-term study (n 1,024) that compared insulin glargine with human NPH insulin for 5 years in the management of type 2 diabetes. The mean cumulative exposure in that study was 4 years. The overall numbers of patients with neoplasms (using the standard Medical Dictionary for Regulatory Activities coding dictionary) occurring during the trial were similar in the two treatment groups 57 patients (11.1%) in the insulin glargine group versus 62 patients (12.3%) in the NPH insulin group, with an RR for insulin glargine of 0.90 (95% CI, ). The RR estimate for all malignant breast tumor cases was calculated to be 0.59, with a 95% CI of Of major importance is an ongoing, placebo-controlled outcome trial testing the injection of insulin glargine in patients with dysglycemia to determine whether targeting normal fasting glucose levels with insulin glargine reduces cardiovascular outcomes compared with standard management. Participants have been followed up for an average of 4 years to date for a total exposure of 50,000 person years. Data are collected related to all major serious health outcomes, including cancers. In light of the questions raised by the recent publications, this committee of experts recently reviewed data related to cancers in both treatment groups and concluded that there is no cause for concern and no reason to alter the design of the study for safety reasons [17]. HEMKENS ET AL. [8] WITHIN THE GERMAN CONTEXT The Hemkens et al. [8] study was published by a joint author team of the German Institute for Quality and Efficiency in Health Care (IQWiG) and the Research Institute of the AOK. Of note might also be that no ethical committee was involved and the data were not anonymized (the pseudonymization process remained unspecified) despite the fact that patients did not give their informed consent for the purpose of the study. There has been widespread attention to these publications and the analysis by Hemkens et al. [8] in particular, with a perceived higher cancer risk for patients on insulin glargine. This awareness was further boosted in the mass media, including television statements by the head of the IQWiG and senior author of the Hemkens et al. [8] study arguing that, in Germany alone, an extrapolated 400 4,000
5 Ehninger, Schmidt 1173 potential excess cancer cases per 1.5 years might be a result of the use of insulin glargine [18, 19]. Such statements are in noticeable contrast to the hypothesis-generating nature of the Hemkens et al. [8] study as explicitly defined in the publication. The publicly perceived higher risk for cancer led to substantial uncertainty among patients and physicians and caused withdrawals of insulin glargine because of cancer fears. One of the authors (G.E.) of the current comment previously opposed this perception and its consequences [20] because of substantial flaws in the study leading to medically wrong conclusions. We even would be willing to go further in claiming that the obvious deficiencies of these analyses were recognized by the authors but were dismissed. The IQWiG was founded in One of its tasks is to evaluate the benefit of pharmaceutical drugs with the intention of informing the federal committee Gemeinsamer Bundesausschuss (G-BA). The G-BA is the heading board within the self-governing health care system and makes binding decisions on reimbursement of drugs. A recent report of the IQWiG (March 2009) evaluated the benefit of long-acting insulins in the treatment of type 2 diabetes [21]. During the planning of this assessment, staff members of the IQWiG copublished a Cochrane review that documented a lower risk for symptomatic nocturnal hypoglycemia [22]. The IQWiG assessment itself describes a significantly lower risk for severe as well as symptomatic hypoglycemias with insulin glargine than with long-acting human insulin (NPH) as a result of a meta-analysis based on individual patient data [21]. In contrast to the benefit of a lower risk for severe hypoglycemia with insulin glargine, the superiority in terms of a lower risk for symptomatic hypoglycemia was questioned by the report later on because of a newly introduced adjusted decision limit. This limit refers to a study by Wood et al. [23] indicating that, without blinding, the effects of interventions tend to be overestimated in trials with subjective outcomes. However, they concede that there is no simple or widely accepted method to integrate assessments of risk of bias into meta-analyses. Therefore, the adjusted decision limit can be seen as an invention by the IQWiG. Despite these findings, the resumé documented no incremental benefit for insulin glargine over human insulin (NPH insulin). A potential influence on cancer rates by insulin glargine was also addressed in that report [21], which included only randomized, controlled trials, in line with their general drug assessment policy. The report identifies only one randomized, long-term study that compares insulin glargine with NPH insulin [16]. Although the study showed no evidence for a greater cancer risk with insulin glargine, the report concluded that the number of patients (n 1,024) might have been too small for a definitive judgment of cancer rates. The report did not refer to the analysis by Hemkens et al. [8], which had already been submitted at the time of hearing of the draft report and publication of the final report. CONCLUSIONS Preclinical studies have pointed to possible greater mitogenicity of insulins. Nonetheless, insulin treatment is a cornerstone in the clinical armamentarium to prevent the fatal consequences of diabetes. Whether or not there are differences between different insulin preparations is an important question, but only methodologically sound analyses with clear prespecifications and scientific discussion can contribute to our knowledge. The present analyses and their perception in the media caused and still do cause a lot of concern, and the European Medicines Agency (EMEA) immediately started a review and disclosed, in a press release on July 23, 2009: Concerns over a possible relationship between these medicines and cancer, in particular breast cancer, were raised by four recently published registry studies. The Committee carried out an in-depth review of these studies and their outcomes. Due to methodological limitations the studies were found to be inconclusive and did not allow a relationship between insulin glargine and cancer to be confirmed or excluded. In addition, the Committee noted that the results of the studies were not consistent. The conclusion of the EMEA was:... available data does not provide a cause for concern and that changes to the prescribing advice are therefore not necessary [24]. Nevertheless, concern remains among patients, their relatives, and even their physicians. Hypothesis-generating analyses should only be published if there is a balanced discussion. This was, however, not apparently intended by the authors because they distributed their findings aggressively to the lay press through the IQWiG with alarming headlines that read Insulin analogue glargine possibly increases cancer risk. The lack of information about major cancer risk factors (e.g., BMI and smoking habits), the comparison of two very different groups of patients, and the use of highly questionable statistical approaches make the paper by Hemkens et al. [8] an example of what happens when a comparison is made between apples and oranges. Worse yet, when appropriate statistical methods are abused or abandoned, the result confuses rather than clarifies a field that needs sound science rather than sensationalism. The words of Peacock and Smeeth ring in one s ears:...claims of harm not backed by adequate evidence can provoke unnecessary alarms and anxieties, and seriously interfere with good medical practice [1]. AUTHOR CONTRIBUTIONS Conception/Design: Gerhard Ehninger, Alexander Schmidt Collection and/or assembly of data: Gerhard Ehninger, Alexander Schmidt Data analysis and interpretation: Gerhard Ehninger, Alexander Schmidt Manuscript writing: Gerhard Ehninger, Alexander Schmidt
6 1174 It Is Easier to Seed the Buzz Than to Disprove It Final approval of manuscript: Gerhard Ehninger, Alexander Schmidt REFERENCES 1 Pocock SJ, Smeeth L. Insulin glargine and malignancy: An unwarranted alarm. Lancet 2009;374: Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A et al. Type-II diabetes and pancreatic cancer: A meta-analysis of 36 studies. Br J Cancer 2005;92: Larsson S, Mantzoros C, Wolk A. Diabetes mellitus and risk of breast cancer: A meta-analysis. Int J Cancer 2007;121: Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: A meta-analysis. J Natl Cancer Inst 2005;97: Bowker SL, Majumdar SR, Veugelers P et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29: Kurtzhals P, Schaffer L, Sørensen A et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000;49: Agin A, Jeandidier N, Gasser F et al. Glargine blood biotransformation: In vitro appraisal with human insulin immunoassay. Diabetes Metab 2007;33: Hemkens LG, Grouven U, Bender R et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: A cohort study. Diabetologia 2009;52: Smith U, Gale EA. Does diabetes therapy influence the risk of cancer? Diabetologia 2009;52: Jonasson JM, Ljung R, Talbäck M et al. Insulin glargine use and short-term incidence of malignancies a population-based follow-up study in Sweden. Diabetologia 2009;52: SDRN Epidemiology Group. Use of Insulin Glargine and Cancer Incidence in Scotland: A Study From the Scottish Diabetes Research Network Epidemiology Group, Available at download/090818colhounacceptedpaperadjusted.pdf, accessed July 10, Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52: Calle EE, Rodriguez C, Walker-Thurmond K et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348: Renehan AG, Tyson M, Egger M et al. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 2008;371: Erbel S, Reers C, Eckstein VW et al. Proliferation of colo-357 pancreatic carcinoma cells and survival of patients with pancreatic carcinoma are not altered by insulin glargine. Diabetes Care 2008;31: Rosenstock J, Fonseca V, McGill JB et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: Findings from a 5 year randomised, open-label study. Diabetologia 2009;52: McMaster University. Research Team Responds to Concerns About International Insulin Drug Trial. McMaster University news release, August 10, Available at trial.html, accessed August 22, Grill M. Dünger für Krebszellen. Der Spiegel 2009;104: Rummel A. Erhöht Lantus das Krebsrisiko? TV Das Erste, July , German Society for Haematology and Oncology. Keine Steigerung des Krebsrisikos durch Insulin Lantus press release, July 15, Institute for Quality and Efficiency in Health Care. Abschlussbericht: Langwirksame Insulinanaloga zur Behandlung des Diabetes mellitus Typ 2. Cologne, Germany: IQWiG, Available at download/a05 03_Abschlussbericht_Langwirksame_Insulinanaloga_ bei_diabetes_mellitus_typ_2_v1.1.pdf, accessed August 22, Horvath K, Jeitler K, Berghold A et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;(2):CD Wood L, Egger M, Gluud LL et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: Meta-epidemiological study. BMJ 2008;336: European Medicines Agency Press Office. Press Release: European Medicines Agency Update on Safety of Insulin Glargine. London, July, 23, Available at Lantus/ en.pdf, accessed August 4, 2009.
Increased Risk of Cancer with Anti-diabetes Drugs? Cons
Increased Risk of Cancer with Anti-diabetes Drugs? Cons Inje University College of Medicine, Ilsanpaik Hospital, Department of Internal Medicine Dong-Jun Kim Gastroenterology132:2208-2225, 2007 IGF-1 System
More informationSimilar risk of malignancy with insulin glargine and neutral protamine Hagedorn
Letter Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, openlabel study J. Rosenstock 1,2,
More informationIncreased risk of cancer with anti-diabetes drugs? : pros
24 th Spring Congress of Korean Diabetes Association Increased risk of cancer with anti-diabetes drugs? : pros Nan Hee Kim, MD, Ph.D. Professor Korea University Medical School Contents Diabetes and cancer
More informationEASD European Association for the Study of Diabetes
Insulin analogues and cancer: a possible link that needs further investigation Diabetologia, the journal of the (EASD), has just published a series of research papers that have examined a possible link
More informationLong-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women with Type 2 Diabetes.
Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women with Type 2 Diabetes. Wu, J. W., Azoulay, L., Majdan, A., Boivin, J. F., Pollak, M., and Suissa, S. Journal of Clinical
More informationCONSULTANT PHYSICIAN v SANOFI
CASE AUTH/2477/2/12 CONSULTANT PHYSICIAN v SANOFI Conduct of representative A consultant physician alleged that at a hospital diabetes meeting a Sanofi representative had been unprofessional in that she
More informationPositron emission tomography (PET and PET/CT) in recurrent colorectal cancer 1
IQWiG Reports - Commission No. D06-01C Positron emission tomography (PET and PET/CT) in recurrent colorectal cancer 1 Executive Summary 1 Translation of the executive summary of the final report Positronenemissionstomographie
More informationScottish Medicines Consortium
Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationThe influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Diabetologia (2009) 52:1766 1777 DOI 10.1007/s00125-009-1440-6 ARTICLE The influence of glucose-lowering therapies on cancer risk in type 2 diabetes C. J. Currie & C. D. Poole & E. A. M. Gale Received:
More informationIQWiG Reports Commission No. A05-05C. Executive Summary
IQWiG Reports Commission No. A05-05C Glinides in the treatment of diabetes mellitus type 2 1 Executive Summary 1 Translation of the executive summary of the final report Glinide zur Behandlung des Diabetes
More informationSafinamide (Addendum to Commission A15-18) 1
IQWiG Reports Commission No. A15-41 Safinamide (Addendum to Commission A15-18) 1 Addendum Commission:A15-41 Version: 1.1 Status: 29 October 2015 1 Translation of addendum A15-41 Safinamid (Addendum zum
More informationExecutive Summary. Evaluation of the therapeutic benefits and harms of exenatide 1. IQWiG Reports - Commission No. A05-23
IQWiG Reports - Commission No. A05-23 Evaluation of the therapeutic benefits and harms of exenatide 1 Executive Summary 1 Translation of the executive summary of the final report Bewertung des therapeutischen
More informationUNCORRECTED PROOF. AUTHOR'S PROOF! Diabetologia DOI /s ARTICLE 2
DOI 10.1007/s00125-009-1440-6 1 3 ARTICLE 2 4 The influence of glucose-lowering therapies on cancer risk 5 in type 2 diabetes 6 C. J. Currie & C. D. Poole & E. A. M. Gale 7 Received: 19 May 2009 /Accepted:
More informationHong Qiu ALL RIGHTS RESERVED
2011 Hong Qiu ALL RIGHTS RESERVED ANTI-DIABETIC TREATMENT AND CANCER OCCURRENCE AMONG PATIENTS WITH TYPE II DIABETES MELLITUS By HONG QIU A dissertation submitted to the School of Public Health University
More informationDiabetes mellitus is associated with serious long-term
CMAJ Research Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis Sumeet R. Singh BScPhm MSc, Fida Ahmad MSc, Avtar Lal MD PhD, Changhua Yu MD MSc, Zemin Bai
More informationTitle:BE SMART AGAINST CANCER! A school-based program concerning cancer-related risk behavior: a randomized controlled intervention study
Author's response to reviews Title:BE SMART AGAINST CANCER! A school-based program concerning cancer-related risk behavior: a randomized controlled intervention study Authors: Friederike Stölzel (friederike.stoelzel@uniklinikum-dresden.de)
More informationCOMPUS Vol 2, Issue 8 December 2008
OPTIMAL THERAPY REPORT COMPUS Vol 2, Issue 8 December 2008 Gap Analysis and Key Messages for the Prescribing and Use of Insulin Analogues Supporting Informed Decisions À l appui des décisions éclairées
More informationThese results are supplied for informational purposes only.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationThiazolidinediones and the risk of bladder cancer: A cohort study. R Mamtani, K Haynes, WB Bilker, DJ Vaughn, BL Strom, K Glanz, JD Lewis
Thiazolidinediones and the risk of bladder cancer: A cohort study R Mamtani, K Haynes, WB Bilker, DJ Vaughn, BL Strom, K Glanz, JD Lewis Study objective To investigate the risk of bladder cancer associated
More informationSponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationIQWiG Reports Commission No. A Dulaglutide
IQWiG Reports Commission No. A15-07 Dulaglutide Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.7 of the dossier assessment Dulaglutid Nutzenbewertung
More informationLong-term effects of insulin glargine on the risk of breast cancer
Diabetologia (2011) 54:2254 2262 DOI 10.1007/s00125-011-2190-9 ARTICLE Long-term effects of insulin glargine on the risk of breast cancer S. Suissa & L. Azoulay & S. Dell Aniello & M. Evans & J. Vora &
More informationSitagliptin/metformin Benefit assessment according to 35a Social Code Book V 1
IQWiG Reports Commission No. A13-03 Sitagliptin/metformin Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Sitagliptin/Metformin
More informationEarly benefit assessment of new drugs 5-year experiences of AMNOG (from IQWiG s point of view)
Early benefit assessment of new drugs 5-year experiences of AMNOG (from IQWiG s point of view) Stefan Lange, MD, PhD Deputy director Institute for Quality and Efficiency in Health Care (IQWiG) Skipka G,
More informationNew basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011
New basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011 Presenter Disclosure I have received the following
More informationPramlintide & Weight. Diane M Karl MD. The Endocrine Clinic & Oregon Health & Science University Portland, Oregon
Pramlintide & Weight Diane M Karl MD The Endocrine Clinic & Oregon Health & Science University Portland, Oregon Conflict of Interest Speakers Bureau: Amylin Pharmaceuticals Consultant: sanofi-aventis Grant
More informationinsulin degludec (Tresiba ) is not recommended for use within NHS Scotland.
insulin degludec (Tresiba ) 100units/mL solution for injection in pre-filled pen or cartridge and 200units/mL solution for injection in pre-filled pen SMC No. (856/13) Novo Nordisk 08 March 2013 The Scottish
More informationLinagliptin Renewed benefit assessment according to 35a Paragraph 5b Social Code Book V 1
IQWiG Reports Commission No. A12-11 Linagliptin Renewed benefit assessment according to 35a Paragraph 5b Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment ( Linagliptin
More informationType 2 Diabetes and Cancer: Is there a link?
Type 2 Diabetes and Cancer: Is there a link? Sonali Thosani, MD Assistant Professor Department of Endocrine Neoplasia & Hormonal Disorders MD Anderson Cancer Center No relevant financial disclosures Objectives
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationOsimertinib (lung cancer)
IQWiG Reports Commission No. A16-14 Osimertinib (lung cancer) Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Osimertinib
More informationDoes diabetes therapy influence the risk of cancer?
DOI 10.1007/s00125-009-1441-5 EDITORIAL Does diabetes therapy influence the risk of cancer? U. Smith & E. A. M. Gale # Springer-Verlag 2009 Keywords Cancer. Insulin analogues. Insulin therapy. Metformin.
More informationGLOSSARY OF GENERAL TERMS
GLOSSARY OF GENERAL TERMS Absolute risk reduction Absolute risk reduction (ARR) is the difference between the event rate in the control group (CER) and the event rate in the treated group (EER). ARR =
More informationAssessment of the benefit of screening in persons under 55 years of age with a family history of colorectal cancer 1
IQWiG Reports Commission No. S11-01 Assessment of the benefit of screening in persons under 55 years of age with a family history of colorectal cancer 1 Executive Summary 1 Translation of the executive
More informationEffective Health Care Program
Comparative Effectiveness Review Number 57 Effective Health Care Program Methods for Insulin Delivery and Glucose Monitoring: Comparative Effectiveness Executive Summary Background Diabetes mellitus is
More informationFinland and Sweden and UK GP-HOSP datasets
Web appendix: Supplementary material Table 1 Specific diagnosis codes used to identify bladder cancer cases in each dataset Finland and Sweden and UK GP-HOSP datasets Netherlands hospital and cancer registry
More informationSystematic Reviews. Simon Gates 8 March 2007
Systematic Reviews Simon Gates 8 March 2007 Contents Reviewing of research Why we need reviews Traditional narrative reviews Systematic reviews Components of systematic reviews Conclusions Key reference
More informationType 2 Diabetes Use of Insulin. Today 5/24/10. Robert J. Rushakoff, MD
Type 2 Diabetes Use of Insulin Robert J. Rushakoff, MD Professor of Medicine University of California, San Francisco robert.rushakoff@ucsf.edu Today Quick Year in Review Why do some patients need to take
More informationNOVO NORDISK v SANOFI-AVENTIS
CASE AUTH/2152/8/08 NOVO NORDISK v SANOFI-AVENTIS Promotion of Lantus Novo Nordisk complained about a mailer and two leavepieces produced by Sanofi-Aventis that promoted Lantus (insulin glargine). Novo
More informationFinal Report 22 January 2014
Final Report 22 January 2014 Cohort Study of Pioglitazone and Cancer Incidence in Patients with Diabetes Mellitus, Follow-up 1997-2012 Kaiser Permanente Division of Research Assiamira Ferrara, MD, Ph.D.
More informationinsulin degludec/liraglutide 100 units/ml / 3.6mg/mL solution for injection pre-filled pen (Xultophy ) SMC No. (1088/15) Novo Nordisk A/S
insulin degludec/liraglutide 100 units/ml / 3.6mg/mL solution for injection pre-filled pen (Xultophy ) SMC No. (1088/15) Novo Nordisk A/S 4 September 2015 The Scottish Medicines Consortium (SMC) has completed
More informationGuselkumab (plaque psoriasis)
IQWiG Reports Commission No. A18-24 Guselkumab (plaque psoriasis) Addendum to Commission A17-60 1 Addendum Commission: A18-24 Version: 1.0 Status: 27 April 2018 1 Translation of addendum A18-24 Guselkumab
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine. Study Identifiers: NCT
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationGSK Medicine: Study No.: Title: Rationale: Objectives: Indication: Study Investigators/Centers: Research Methods:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationInvolvement of people affected
Involvement of people affected in the dossier assessment 1 1 Translation of the document Beteiligung von Betroffenen bei der Dossierbewertung (Version 1.1; Status: 28 July 2017). Please note: This translation
More informationElectronic Medical Record. Incidence over Six Years Comparing New Users of Glargine. with New Users of NPH Insulin
Electronic Medical Record Cancer Incidence over Six Years Comparing New Users of Glargine with New Users of NPH Insulin The Harvard community has made this article openly available. Please share how this
More informationRisk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin
Diabetologia (2006) 49: 930 936 DOI 10.1007/s00125-006-0176-9 ARTICLE J. M. M. Evans. S. A. Ogston. A. Emslie-Smith. A. D. Morris Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes:
More informationOnline Supplementary Material
Section 1. Adapted Newcastle-Ottawa Scale The adaptation consisted of allowing case-control studies to earn a star when the case definition is based on record linkage, to liken the evaluation of case-control
More informationBeyond Controlling for Confounding: Design Strategies to Avoid Selection Bias and Improve Efficiency in Observational Studies
September 27, 2018 Beyond Controlling for Confounding: Design Strategies to Avoid Selection Bias and Improve Efficiency in Observational Studies A Case Study of Screening Colonoscopy Our Team Xabier Garcia
More informationMetformin associated with lower cancer mortality in type 2 diabetes (ZODIAC-16).
Diabetes Care Publish Ahead of Print, published online November 16, 2009 Metformin associated with lower cancer mortality in type 2 diabetes (ZODIAC-16). Authors: Gijs.W. Landman MD 1,2, Nanne Kleefstra
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationSponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationExecutive Summary. Positron emission tomography (PET and PET/CT) in malignant lymphoma 1. IQWiG Reports Commission No. D06-01A
IQWiG Reports Commission No. D06-01A Positron emission tomography (PET and PET/CT) in malignant lymphoma 1 Executive Summary 1 Translation of the executive summary of the final report Positronenemissionstomographie
More informationComparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary
Number 14 Effective Health Care Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary Background and Key Questions
More informationRecent developments for combining evidence within evidence streams: bias-adjusted meta-analysis
EFSA/EBTC Colloquium, 25 October 2017 Recent developments for combining evidence within evidence streams: bias-adjusted meta-analysis Julian Higgins University of Bristol 1 Introduction to concepts Standard
More informationInsulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children
Insulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children December 2008 This technology summary is based on information available at the time of research and a limited literature
More informationDüsseldorf, Germany 24 th February, Response from Bernd Richter, written in his personal capacity, to the
Düsseldorf, Germany 24 th February, 2017 Response from Bernd Richter, written in his personal capacity, to the Essential Medicines List (EML) 2017 Application for the inclusion of long acting insulin analogues
More informationInsulin detemir (Levemir)... 2 Leuprorelin... 4 Levetiracetam (Keppra)... 5 Budesonide/eformoteral (Symbicort) widening access...
August 2005 PTAC Meeting PTAC minutes are published in accordance with the following definitions from the PTAC Guidelines 2002: Minute means that part of the record of a PTAC or Sub-committee meeting (including
More informationLower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6 10
6 Diabetes Care Volume 41, January 2018 PERSPECTIVES IN CARE Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6 10 https://doi.org/10.2337/dc17-1223
More informationPHARMACISTS INTERACTIVE EDUCATION CASE STUDIES
PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES Disclaimer: The information in this document is not a substitute for clinical judgment in the care of a particular patient. CADTH is not liable for any damages
More informationCancer occurrence in Danish diabetes patients: Duration and insulin effects
Cancer occurrence in Danish diabetes patients: Duration and insulin effects Compiled Thursday 20 th October, 2011, 16:12 from: C:/Bendix/Steno/DMregister/NDR/projects/Cancer/papers/P1/Updated2009DMCA4.tex
More informationPerampanel Benefit assessment according to 35a Social Code Book V 1
IQWiG Reports Commission No. A14-16 Perampanel Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Perampanel Nutzenbewertung
More informationDiabetes: Three Core Deficits
Diabetes: Three Core Deficits Fat Cell Dysfunction Impaired Incretin Function Impaired Appetite Suppression Obesity and Insulin Resistance in Muscle and Liver Hyperglycemia Impaired Insulin Secretion Islet
More informationNivolumab Addendum to Commission A
IQWiG Reports Commission No. A15-58 Nivolumab Addendum to Commission A15-32 1 Addendum Commission:A15-58 Version: 1.0 Status: 13 January 2016 1 Translation of addendum A15-58 Nivolumab Addendum zum Auftrag
More informationGSK Clinical Study Register
In February 2013, GlaxoSmithKline (GSK) announced a commitment to further clinical transparency through the public disclosure of GSK Clinical Study Reports (CSRs) on the GSK Clinical Study Register. The
More informationBlood Pressure and Complications in Individuals with Type 2 Diabetes and No Previous Cardiovascular Disease. ID BMJ
1 Blood Pressure and Complications in Individuals with Type 2 Diabetes and No Previous Cardiovascular Disease. ID BMJ 2016.033440 Dear Editor, Editorial Committee and Reviewers Thank you for your appreciation
More informationEmpagliflozin (Jardiance ) for the treatment of type 2 diabetes mellitus, the EMPA REG OUTCOME study
Empagliflozin (Jardiance ) for the treatment of type 2 diabetes mellitus, the EMPA REG OUTCOME study POSITION STATEMENT: Clinicians should continue to follow MHRA advice and NICE technology appraisal guidance
More informationPostmenopausal hormone therapy and cancer risk
International Congress Series 1279 (2005) 133 140 www.ics-elsevier.com Postmenopausal hormone therapy and cancer risk P. Kenemans*, R.A. Verstraeten, R.H.M. Verheijen Department of Obstetrics and Gynaecology,
More informationMeta-analyses: analyses:
Meta-analyses: analyses: how do they help, and when can they not? Lee Hooper Senior Lecturer in research synthesis & nutrition l.hooper@uea.ac.uk 01603 591268 Aims Systematic Reviews Discuss the scientific
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency London, 15 November 2007 Doc. Ref. EMEA/CHMP/EWP/517497/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON CLINICAL EVALUATION OF MEDICINAL PRODUCTS USED
More informationIndividualising Insulin Regimens: Premixed or basal plus/bolus?
Individualising Insulin Regimens: Premixed or basal plus/bolus? Dr. Ted Wu Director, Diabetes Centre, Hospital Sydney, Australia Turkey, April 2015 Centre of Health Professional Education Optimising insulin
More informationClinical Evidence: Asking the Question and Understanding the Answer. Keeping Up to Date. Keeping Up to Date
Clinical Evidence: Asking the Question and Understanding the Answer Keeping Up to Date 5,000? per day 1,500 per day 95 per day Keeping Up to Date 5,000? per day 1,500 per day 95 per day 1 Bias Bias refers
More informationState of the art pharmacoepidemiological study designs for post-approval risk assessment
State of the art pharmacoepidemiological study designs for post-approval risk assessment Cardiac Safety Research Consortium Think Tank Round Table Meeting Thursday, March 6, 2014 Jennifer L. Lund, PhD
More informationSystematic Reviews and Meta- Analysis in Kidney Transplantation
Systematic Reviews and Meta- Analysis in Kidney Transplantation Greg Knoll MD MSc Associate Professor of Medicine Medical Director, Kidney Transplantation University of Ottawa and The Ottawa Hospital KRESCENT
More informationOVERALL HEALTH EFFECTS OF SWEDISH MATCH SNUS PRODUCTS
OVERALL HEALTH EFFECTS OF SWEDISH MATCH SNUS PRODUCTS Lester Jao Lacorte, MD, CCRP Medical Officer Office of Science Center for Tobacco Products U.S. Food and Drug Administration DISCLAIMER 1 The information
More informationBiostatistics and Epidemiology Step 1 Sample Questions Set 1
Biostatistics and Epidemiology Step 1 Sample Questions Set 1 1. A study wishes to assess birth characteristics in a population. Which of the following variables describes the appropriate measurement scale
More informationThe Epidemiology of Diabetes and Cancer
Curr Diab Rep (14) 14:535 DOI 1.17/s11892-14-535-8 DIABETES AND OTHER DISEASES-EMERGING ASSOCIATIONS (JJ NOLAN, SECTION EDITOR) The Epidemiology of Diabetes and Cancer Bendix Carstensen Marit Eika Jørgensen
More informationMOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
More informationSystematic reviews and meta-analyses of observational studies (MOOSE): Checklist.
Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist. MOOSE Checklist Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease:
More informationManuscript ID BMJ entitled "Benzodiazepines and the Risk of Allcause Mortality in Adults: A Cohort Study"
12-Jan-2017 Dear Dr. Patorno Manuscript ID BMJ.2016.036319 entitled "Benzodiazepines and the Risk of Allcause Mortality in Adults: A Cohort Study" Thank you for sending us your paper. We sent it for external
More informationSaxagliptin/metformin Benefit assessment according to 35a Social Code Book V 1
IQWiG Reports Commission No. A12-16 Saxagliptin/metformin Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Saxagliptin/Metformin
More informationGRADE Evidence Profiles on Long- and Rapid-Acting Insulin Analogues for the treatment of Diabetes Mellitus [DRAFT] October 2007
GRADE Evidence Profiles on Long- and Rapid-Acting Insulin Analogues for the treatment of Diabetes Mellitus October 2007 Canadian Agency for Drugs and Technologies in Health Disclaimer This report is prepared
More informationIdelalisib Benefit assessment according to 35a Social Code Book V 1
IQWiG Reports Commission No. A14-35 Idelalisib Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Assessment module I, Sections I 2.1 to I 2.9, and Assessment module II,
More informationSUPPLEMENTARY DATA. Supplementary Figure S1. Search terms*
Supplementary Figure S1. Search terms* *mh = exploded MeSH: Medical subject heading (Medline medical index term); tw = text word; pt = publication type; the asterisk (*) stands for any character(s) #1:
More informationReplicating Randomised Trials of Treatments in Observational Settings Using Propensity Scores Fisher s Aphorisms
Replicating Randomised Trials of Treatments in Observational Settings Using Propensity Scores Fisher s Aphorisms Nick Freemantle PhD Professor of Clinical Epidemiology & Biostatistics Assessing Causation
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Policy Reference Number: CP.PMN.53 Effective Date: 09.12.17 Last Review Date: 11.18 Line of Business: Medicaid, HIM-Medical Benefit Revision Log See Important Reminder at the end of this
More informationObesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, :15 a.m. 11:00 a.m.
Obesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, 2018 10:15 a.m. 11:00 a.m. Type 2 diabetes mellitus (T2DM) is closely associated with obesity, primarily through the link
More informationPlacename CCG. Policies for the Commissioning of Healthcare
Placename CCG Policies for the Commissioning of Healthcare Policy for the funding of insulin pumps and continuous glucose monitoring devices for patients with diabetes 1 Introduction 1.1 This document
More informationRamucirumab (colorectal cancer)
IQWiG Reports Commission No. A16-50 Ramucirumab (colorectal cancer) Addendum to Commission A16-10 1 Addendum Commission:A16-50 Version: 1.0 Status: 27 July 2016 1 Translation of addendum A16-10 Ramucirumab
More informationInsulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes
Insulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationiglarlixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L
Diabetes Ther (2018) 9:373 382 https://doi.org/10.1007/s13300-017-0336-6 BRIEF REPORT iglarlixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post
More informationEmpagliflozin/metformin
IQWiG Reports Commission No. A16-13 Empagliflozin/metformin Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Empagliflozin/Metformin
More informationNew Medicine Assessment
New Medicine Assessment Insulin Glargine 300 units/ml (Toujeo ) Treatment of type 2 diabetes mellitus in adults Recommendation: Amber 0 Insulin glargine 300 units/ml (Toujeo ) is recommended as an option
More informationDPP-4 inhibitor use and risk of diabetic retinopathy: a new safety issue of a safe drug Nam Hoon Kim
DPP-4 inhibitor use and risk of diabetic retinopathy: a new safety issue of a safe drug Nam Hoon Kim Endocrinology of Metabolism, Korea University College of Medicine Conflict of interest disclosure None
More informationEvidence Based Medicine
Course Goals Goals 1. Understand basic concepts of evidence based medicine (EBM) and how EBM facilitates optimal patient care. 2. Develop a basic understanding of how clinical research studies are designed
More informationGENERAL COMMENTS. The Task Force Process Should be Fully Open, Balanced and Transparent
December 9, 2013 Submitted Electronically United States Preventive Services Task Force c/o Dr. Robert Cosby Agency for Healthcare Research and Quality 540 Gaither Road Rockville, MD 20850 RE: USPSTF Draft
More informationACR OA Guideline Development Process Knee and Hip
ACR OA Guideline Development Process Knee and Hip 1. Literature searching frame work Literature searches were developed based on the scenarios. A comprehensive search strategy was used to guide the process
More informationIntervention empagliflozin + metformin N = 765 patients with events n (%)
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
More informationNOTICE. Release of final Health Canada document: Standards for Clinical Trials in Type 2 Diabetes in Canada
September 24, 2007 NOTICE Our file number: 07-122151-509 Release of final Health Canada document: Standards for Clinical Trials in Type 2 Diabetes in Canada The final version of the Health Canada guidance
More information